Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: Subgroup analyses in the scandinavian simvastatin survival study

Archives of Internal Medicine

Volumn 159, Issue 22, 1999, Pages 2661-2667

  Haffner, Steven M ^a,f   Alexander, Charles M ^b   Cook, Thomas J ^b   Boccuzzi, Stephen J ^b   Musliner, Thomas A ^b   Pedersen, Terje R ^c   Kjekshus, John ^d   Pyörälä, Kalevi ^e  

^a University of Texas Health Science Center   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c AKER UNIVERSITY HOSPITAL   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF EASTERN FINLAND   (Finland)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; GLUCOSE; PLACEBO; SIMVASTATIN;

ADULT; ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; BLOOD GLUCOSE; CHOLESTEROL, LDL; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE INTOLERANCE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; PROGNOSIS; SCANDINAVIA; SIMVASTATIN; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0033611310     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.22.2661     Document Type: Article

References (28)

1. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham Study. Diabetes Care. 1979;2:120-126.
2. Wingard DL, Barrett-Connor E. Heart disease and diabetes. In: National Diabetes Data Group, ed. Diabetes in America 2nd ed. Washington, DC: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995:429-448. NIH publication 95-1468.
3. Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev. 1987;3:463-524
4. Stamler J, Vaccaro O, Neaton JD. Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-444.
5. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
6. Abbott RD, Donahue RP, Kannel WB, Wilson PW. The impact of diabetes on survival following myocardial infarction in men vs. women: the Framingham Study [published correction appears in JAMA. 1989;261:1884]. JAMA. 1988:260:3456-3460.
7. Herliz J, Karlson BW, Edvardsson N, Emanuelsson H, Hjalmarson Å. Prognosis in diabetics with chest pain or other symptoms suggestive of acute myocardial infarction. Cardiology. 1992;80:237-245.
8. Miettinen H, Lehto S, Salomaa VV. et al. Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care. 1998;21:69-75.
9. Haffner SM. Impaired glucose tolerance: is it relevant for cardiovascular disease? Diabetologia. 1997;40(suppl 2):S138-S140.
10. Morris ML, Eastman RC. Is there a glycemic threshold for mortality risk? Diabetes Care. 1998;21:334-335.
11. Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policeman Study. Diabetes Care. 1998;21:360-367.
12. Meigs JB, Nathan DM, Wilson PW, Cupples LA, Singer DE. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance: the Framingham Offspring Study. Ann Intern Med. 1998;128:524-533.
13. Haffner SM. Technical review: management of dyslipidemia in adults with diabetes. Diabetes Care. 1998;21:160-178.
14. Alexander CM, Landsman PB, Boccuzzi SJ, Berger ML. Impaired fasting glucose, lipid levels and prevalence of coronary heart disease: a U.S. population perspective. Diabetes. 1998;47(suppl I):A75.
15. Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) [published correction appears in Diabetes Care. 1997; 20:1048]. Diabetes Care. 1997;20:614-620.
16. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 1998;98:2513-2519.
17. The Long-term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
18. American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183-1197.
19. The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
20. The Scandinavian Simvastatin Survival Study Group. Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. Am J Cardiol. 1993;71:393-400.
21. Kost GJ, Bowen TP. New whole blood methods and instruments: glucose measurements and test menus for critical care. J Int Fed Clin Chem. 1991;3:160-172.
22. Cox DR. Regression methods of life tables (with discussion). J R Stat Soc Ser B Method. 1972;34:187-200.
23. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 1998; 279:1615-1622.
24. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310:452-454.
25. Sackett DL, Haynes RB. Summarizing the effects of therapy: a new table and some terms. ACP J Club. 1997;127:A15-A16.
26. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension: SHEP Cooperative Research Group. JAMA. 1997;278:212-216.
27. National Cholesterol Education Program. Second Report of the Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults. Washington, DC: National Heart Lung and Blood Institute; 1993. NIH publication 93-3095.
28. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care. 1999;22(suppl 1):S56-S59.